Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

2.0K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
2.0K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

2.7K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.7K
Adrenergic Agonists: Direct-Acting Agents01:30

Adrenergic Agonists: Direct-Acting Agents

2.7K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
2.7K
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

2.0K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
2.0K
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

2.5K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.5K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

2.3K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiac Intensive Care Unit Appropriate Patient Selection and Triage: A Scientific Statement From the American Heart Association.

Circulation·2026
Same author

Outcomes of Venous-Arterial Extracorporeal Membrane Oxygenation Therapy in Acute Pulmonary Embolism: A Single-Center Experience.

Journal of thrombosis and thrombolysis·2026
Same author

Predictors of Long-Term Outcomes in Hypertrophic Cardiomyopathy: The NHLBI HCM Registry.

JAMA·2026
Same author

Real-world incidence of cancer therapy-related cardiac dysfunction in a large, diverse, and contemporary cohort.

ESC heart failure·2026
Same author

Clinical risk prediction models for worsening heart failure events and all-cause mortality in adults with mild-to-moderate chronic kidney disease.

ESC heart failure·2026
Same author

State-of-the-Art Update in Extracorporeal Cardiopulmonary Resuscitation for Out-of-hospital Cardiac Arrest.

Critical care clinics·2025

Related Experiment Video

Updated: May 3, 2026

Contractility Measurements on Isolated Papillary Muscles for the Investigation of Cardiac Inotropy in Mice
06:22

Contractility Measurements on Isolated Papillary Muscles for the Investigation of Cardiac Inotropy in Mice

Published on: September 17, 2015

14.7K

Inotropes.

Gary S Francis1, Jason A Bartos1, Sirtaz Adatya1

  • 1Department of Medicine, Cardiovascular Division, University of Minnesota, Minneapolis, Minnesota.

Journal of the American College of Cardiology
|February 18, 2014
PubMed
Summary
This summary is machine-generated.

New inotropic drugs are needed to improve cardiac output in cardiogenic shock without increasing mortality. Research focuses on agents that enhance myocardial contractility while minimizing risks like arrhythmia and ischemia.

Keywords:
acute heart failurecardiogenic shockinotrope

More Related Videos

Author Spotlight: Innovative Methods in Lymphedema and Hypertension Research
08:46

Author Spotlight: Innovative Methods in Lymphedema and Hypertension Research

Published on: March 22, 2024

1.6K
Designing a Bioreactor to Improve Data Acquisition and Model Throughput of Engineered Cardiac Tissues
12:28

Designing a Bioreactor to Improve Data Acquisition and Model Throughput of Engineered Cardiac Tissues

Published on: June 2, 2023

3.6K

Related Experiment Videos

Last Updated: May 3, 2026

Contractility Measurements on Isolated Papillary Muscles for the Investigation of Cardiac Inotropy in Mice
06:22

Contractility Measurements on Isolated Papillary Muscles for the Investigation of Cardiac Inotropy in Mice

Published on: September 17, 2015

14.7K
Author Spotlight: Innovative Methods in Lymphedema and Hypertension Research
08:46

Author Spotlight: Innovative Methods in Lymphedema and Hypertension Research

Published on: March 22, 2024

1.6K
Designing a Bioreactor to Improve Data Acquisition and Model Throughput of Engineered Cardiac Tissues
12:28

Designing a Bioreactor to Improve Data Acquisition and Model Throughput of Engineered Cardiac Tissues

Published on: June 2, 2023

3.6K

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Inotropes are crucial for acute cardiogenic shock resuscitation.
  • Severe heart failure and cardiogenic shock involve reduced myocardial contractile force.
  • Current inotropes increase cardiac output but raise mortality via tachycardia and increased myocardial oxygen demand, leading to ischemia and arrhythmia.

Purpose of the Study:

  • To review the mechanism of action and clinical utility of established inotropic agents.
  • To provide an update on novel inotropic drug development for physicians.
  • To highlight the need for inotropic agents that improve systolic performance without increasing myocardial oxygen consumption.

Main Methods:

  • Literature review of older and newer inotropic agents.
  • Analysis of mechanisms of action and clinical outcomes.
  • Discussion of current trends and future directions in inotropic therapy.

Main Results:

  • Older inotropes are widely used but carry significant risks.
  • Newer inotropic agents are under development to mitigate adverse effects.
  • The field of inotropic therapy is evolving rapidly.

Conclusions:

  • There is a critical need for safer inotropic agents in managing cardiogenic shock.
  • Future inotropic drugs aim to enhance cardiac contractility without detrimental side effects.
  • Advancements in pharmacology promise improved treatments for heart failure and cardiogenic shock.